Search or
𝛼SK
𝛼SKbullish
Daiichi Sankyo (4568 JP): Enhertu Drives Beat-And-Raise Q2FY25; Pipeline Progress Boosts Visibility
417 Views01 Nov 2024 08:30
SUMMARY
- Daiichi Sankyo (4568 JP) announced better-than-expected Q2FY25 result, with all key parameters exceeding expectation. Q2 revenue increased 19% to ¥447B, mainly driven by 44% growth in Enhertu sales to ¥132B.
- Daiichi Sankyo has raised FY25 guidance to reflect the positive effect from foreign exchange by the depreciation of Yen and strong performance of global products.
- Enhertu FY25 product sales guidance was raised by ¥15B to ¥523B. Despite recent clinical trial setback, Dato-DXd is expected to get FDA approval for the treatment of NSCLC in December.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Daiichi Sankyo (4568 JP): Strong FY25 Result; Guidance Initiated for FY26; ¥200B Buyback Announced26 Apr 2025
- Daiichi Sankyo (4568 JP): Mixed Q3FY25 Result; FY25 Net Profit Guidance Raised; New CEO Appointed03 Feb 2025
- Daiichi Sankyo (4568 JP): US Approval for Second ADC Drug to Drive Accelerated Growth21 Jan 2025
- Daiichi Sankyo (4568 JP): Starts FY25 on Firm Note; Enhertu Flying Higher Highs; Guidance Reaffirmed31 Jul 2024
- Daiichi Sankyo (4568 JP): FY24 Ends on Strong Note; Initiates FY25 Guidance; ¥200B Buyback Announced25 Apr 2024
- Daiichi Sankyo (4568 JP): Second Time FY24 Guidance Raise; Event Heavy FY25 With 2 New Drug Approval15 Mar 2024
x